Afami-cel therapy leads to regression of large pleural-based thoracic metastasis in synovial sarcoma.
re-expansion, dyspnea
REGRESSION, METASTASES, PLEURAL METASTASIS, METASTATIC DISEASE
In Patient A, afami-cel was associated with reductions in metastatic disease in hemithorax, including regression of a large left lung pleural metastasis that crossed the midline at baseline (Patient A, upper right and upper left panels, respectively) and re-expansion of the right lung, as shown on a computed tomography scan at Week 12 post−afami-cel (Patient A, lower right panel, arrow), associated with patient-reported improvement in exertional dyspnea. In Patient B, afami-cel was associated with overall reduction in left lung pleural metastases including complete resolution of one pleural metastasis (Patient B, lower right panel, arrow). BOR, best overall response; MAGE-A4, melanoma-associated antigen A4; PR, partial response; SLD, sum of longest diameter; TTR, time to response.
